What Is the Best Pacemaker on the Market?

There is no single best pacemaker on the market, because the device that works well for one person can be entirely wrong for another. The choice depends on what kind of heart rhythm problem you have, whether you need pacing in one chamber or two, how active you are, how your body handles implanted hardware, and even your risk of future infections. What the evidence does show is that meaningful differences exist between pacing technologies, between manufacturers, and between newer and older device designs. Understanding those differences puts you in a much better position to have an informed conversation with your cardiologist.

Single-Chamber Versus Dual-Chamber Devices

The most fundamental decision in pacemaker selection is whether you need a single-chamber or dual-chamber device. A single-chamber pacemaker has one lead, typically placed in the right ventricle. A dual-chamber pacemaker has two leads, one in the right atrium and one in the right ventricle, allowing the device to coordinate the timing between the upper and lower chambers of your heart.

For people with atrioventricular (AV) block, where signals between the atrium and ventricle are delayed or interrupted, the evidence has been mixed. A large trial published in the New England Journal of Medicine found no significant difference in death rates or cardiovascular events between single-chamber and dual-chamber pacing over the first several years after implantation in elderly patients with high-grade AV block.¹ However, a much larger and more recent nationwide cohort study found that dual-chamber pacemakers were associated with lower rates of death, heart failure, new atrial fibrillation, and stroke compared to single-chamber devices in patients with AV block.²

A Cochrane systematic review pooling data from multiple trials found a clear advantage for dual-chamber pacing in preventing pacemaker syndrome, an unpleasant collection of symptoms like dizziness, fatigue, and shortness of breath that occurs when the heart’s chambers beat out of sync. Dual-chamber devices also showed a statistically significant benefit in preventing atrial fibrillation and a modest edge in exercise capacity.³ In short, dual-chamber pacing tends to feel better and keeps heart rhythm more natural, even when it does not always produce a dramatic survival advantage in every study. For most patients in sinus rhythm who need pacing for AV block, dual-chamber is the default recommendation today.

The Rise of Leadless Pacemakers

Traditional pacemakers sit in a small pocket under the skin near the collarbone, with leads threaded through veins into the heart. Leadless pacemakers eliminate that entire setup. They are small capsules, roughly the size of a large vitamin pill, implanted directly inside the heart through a catheter inserted via a leg vein. No chest incision, no pocket, no leads running through veins.

The practical appeal is obvious: no pocket means no pocket infection, and no leads mean no lead fractures or dislodgements. A retrospective study found that conventional pacemakers had far higher rates of electrode dislodgement and pocket-site infection compared to leadless devices.⁴ A large registry-based comparison confirmed that leadless pacemakers had roughly half the rate of device-related complications compared to transvenous pacemakers over six months of follow-up.⁵

But leadless pacemakers are not without trade-offs. That same registry study found that the rate of cardiac perforation or pericardial effusion in the first 30 days was about twice as high with leadless devices compared to transvenous ones, though the absolute numbers were small (under 1% for both).⁵ A study of patients receiving pacemakers after a heart valve procedure also found fewer in-hospital complications with leadless devices and a significantly lower risk of device-related complications in the medium term.⁶

Until recently, leadless pacemakers could only pace a single chamber, limiting them to patients who did not need atrial-ventricular synchronization. That limitation has now changed.

Dual-Chamber Leadless Pacing

The first dual-chamber leadless pacemaker system, which uses two separate capsules communicating wirelessly inside the heart, was tested in a pivotal trial published in the New England Journal of Medicine. The implantation succeeded in over 98% of patients, with both devices successfully implanted and communicating. The primary safety goal was met, though about 10% of patients experienced a serious device- or procedure-related adverse event.⁷ Follow-up data at one year continued to show acceptable safety and performance, with a complication-free rate approaching 89%.⁸

This technology is still early. The complication-free rates are lower than what physicians see with mature transvenous systems, and the long-term durability of two wirelessly communicating capsules remains to be proven over many years. But for patients at high risk of lead-related complications or pocket infections, dual-chamber leadless pacing represents a genuinely new option that did not exist a few years ago.

Conduction System Pacing

Standard right ventricular pacing works, but it has a drawback: it activates the ventricle from a single point at the tip of the lead rather than through the heart’s own electrical wiring. Over time, this unnatural activation pattern can weaken the heart muscle in some patients, a condition called pacing-induced cardiomyopathy.

Conduction system pacing avoids this by placing the lead on or near the heart’s own conduction fibers, either at the His bundle or in the left bundle branch area. The electrical signal then travels through the heart’s natural wiring, producing a more physiological contraction. A study comparing His bundle pacing to conventional right ventricular pacing found that the combined risk of death, heart failure hospitalization, or needing an upgrade to a more complex device was about 25% with His bundle pacing versus 32% with conventional pacing. Heart failure hospitalizations, specifically, dropped from roughly 18% to 12%.⁹

A meta-analysis of nearly 2,800 patients found that conduction system pacing (both His bundle and left bundle branch area approaches) was associated with shorter electrical activation times and better heart function compared to conventional right ventricular pacing, along with trends toward fewer downstream problems like heart failure and atrial fibrillation.¹⁰ One concern with His bundle pacing specifically is that the pacing thresholds tend to be higher and the sensed signals smaller, meaning the device may use more battery power.¹¹ Left bundle branch area pacing has emerged as a technically easier alternative that avoids some of these issues, and reliability modeling for leads used in this approach has predicted very low fracture rates, around 0.02% over ten years.¹²

Biventricular Pacing for Heart Failure

Some patients do not just need their heart rate regulated; they need the left and right ventricles to contract in better coordination. This is the role of cardiac resynchronization therapy (CRT), sometimes called biventricular pacing, which adds a lead to the left ventricle (typically through a vein on the heart’s surface). The MUSTIC trial found that biventricular pacing improved walking distance by about 20%, quality of life by over 30%, and heart function as measured by ejection fraction by around 5 percentage points, with similar improvements whether patients were in normal sinus rhythm or had atrial fibrillation.¹³ CRT devices are a separate category from standard pacemakers and are typically prescribed for patients with heart failure who also have a wide QRS complex on their electrocardiogram, signaling that the ventricles are significantly out of sync.

Battery Life Varies More Than You Might Think

A pacemaker battery that lasts longer means fewer replacement surgeries, and each replacement carries its own risks, including infection. So battery longevity is not just a convenience factor; it directly affects your health over a lifetime of pacing.

A study examining nearly 1,500 dual-chamber transvenous pacemakers that reached their replacement indicator found that median battery life ranged from about 103 months (roughly 8.5 years) for one manufacturer up to about 125 months (over 10 years) for others, a difference that was statistically significant. For single-chamber devices, the range was roughly 105 to 122 months. CRT pacemakers showed even wider variation.¹⁴ These differences are driven partly by battery chemistry. Devices using lithium-manganese dioxide batteries can maintain a stable voltage for a larger portion of their discharge cycle, which allows the device to squeeze more usable life from the same battery.¹⁵

One complication worth knowing about: manufacturers’ projected battery life estimates have sometimes overestimated actual longevity in recent device generations. While real-world device longevity improved during earlier eras, that improvement has plateaued in the most recent devices, even as the projections continued to climb.¹⁶ Ask your doctor what the real-world battery data shows for the specific model being considered, not just the manufacturer’s projection.

Lead Reliability and Manufacturer-Specific Concerns

Leads are the most vulnerable component of a traditional pacemaker system, and not all leads are equal. A systematic review and meta-analysis examining over 14,500 pacing leads found that Abbott (formerly St. Jude Medical) leads had an electrical abnormality rate of about 6%, compared to roughly 1% for Medtronic and Boston Scientific leads. Abbott leads carried nearly eight times the risk of requiring reprogramming and about nine times the risk of needing lead revision or extraction.¹⁷ A single-center study identified the Tendril lead family (an Abbott product) as having particularly high rates of electrical abnormalities, approaching 19%, compared to under 2% for competing designs.¹⁸

When leads do need to come out, bench testing has shown that tensile strength during extraction varies across models. Some leads, like the Solia S and CapSure Fix, showed consistently higher durability regardless of extraction technique, while others performed well only with specific retrieval methods.¹⁹ This matters because lead extraction, while generally successful at rates above 96%, carries a small but real risk of serious complications including death, and more complex extractions have higher complication rates.²⁰

Remote Monitoring Changes How Devices Are Managed

Nearly all modern pacemakers from every major manufacturer can transmit data wirelessly to your doctor’s office. Remote monitoring does not change what the pacemaker does to your heart, but it changes how quickly problems get caught. A randomized trial found that remote monitoring detected clinically important events an average of 117 days sooner than traditional in-office visits, and patients in the remote monitoring group had fewer hospitalizations for atrial arrhythmias and strokes.²¹

A meta-analysis of randomized trials found that remote monitoring of pacemakers detected atrial arrhythmias at a higher rate and reduced in-office visits by roughly one per patient per year, without any compromise in safety or quality of life.²² Alert-based systems that transmit daily and prompt fast clinical responses have been linked to improved survival in broader reviews of cardiac implantable devices.²³ Some manufacturers have moved toward smartphone-based apps for device follow-up, though achieving consistent patient adherence remains a work in progress.²⁴

MRI Compatibility

If you expect to ever need an MRI scan, this should factor into your pacemaker choice. Most modern pacemakers are labeled “MRI conditional,” meaning they can safely go through an MRI under specific conditions (certain field strengths, specific device programming modes, and sometimes restrictions on which body region is scanned). However, “MRI conditional” does not mean artifact-free. The device and leads can distort the MRI image, particularly if the pacemaker is close to the area being scanned. Cardiac MRI in particular can be affected, with some devices causing only mild image distortion while others create larger signal voids that undermine the scan’s diagnostic value.²⁵ If you have a known condition that is likely to require cardiac MRI follow-up, such as certain forms of cardiomyopathy, discuss the imaging implications of specific device models before implantation.

Infection Prevention at Implantation

One of the most feared complications of any pacemaker is infection, which can require complete device and lead removal. The device you choose matters, but so does what happens in the operating room. A large randomized trial tested an antibiotic-eluting envelope that wraps around the pacemaker at the time of implantation. The envelope reduced major device infections by about 40%, from a 1.2% rate in the control group to 0.7% in the envelope group.²⁶ This benefit was most pronounced in patients undergoing device replacements or upgrades, who are at higher baseline infection risk.²⁷ Whether you receive an antibacterial envelope may be as important as the brand of pacemaker, particularly if this is not your first device procedure.

What Happens When Leadless Pacemakers Need to Come Out

One concern with leadless pacemakers has been what happens at end of service. Can the capsule be safely retrieved from inside the heart, or does it have to stay there permanently? The data on this is maturing. A global registry of helix-fixation leadless pacemaker retrievals showed an overall success rate of about 88%, with the most common reason for failure being an inability to access the device’s docking mechanism. The average time between implantation and retrieval attempt was about three years, and the duration of implantation did not significantly affect success rates. Retrieval-related complications occurred in about 4% of patients.²⁸ Similar feasibility has been demonstrated for the tine-based leadless pacemaker design, with successful late retrievals followed by implantation of a new device.²⁹ This is reassuring but not perfect. An 88% retrieval success rate means roughly one in eight attempts does not succeed, leaving an abandoned capsule inside the heart.

Cost Considerations

Leadless pacemakers cost substantially more upfront than transvenous systems. A UK-focused health economics analysis projected that a leadless dual-chamber pacing strategy would cost about £15,400 more per patient over a lifetime compared to a conventional transvenous approach, though it would also reduce the risk of device infection from about 2.2% to 0.2%.³⁰ For single-chamber pacing, a European analysis found that leadless devices were actually cost-effective when accounting for the avoided complications and reduced need for reintervention.³¹ In patients with active device infections who need their old system extracted, implanting a leadless pacemaker during the same procedure can reduce hospital stays and streamline treatment enough to make costs comparable to the conventional path.³² The economics shift depending on your clinical situation: the higher your baseline risk of infection or lead complications, the more financial sense a leadless device makes.

Frailty and Patient Selection

Not every patient is a good candidate for every technology. Frailty, a state of reduced physiological reserve common in older adults, significantly affects outcomes regardless of which pacemaker is chosen. A nationwide analysis of over 16,800 patients undergoing leadless pacemaker implantation found that patients at intermediate or high risk of frailty had roughly five to six times the in-hospital mortality of those at low risk, along with longer hospital stays and higher costs. Complication rates, however, were similar across frailty levels.³³ Whether frailty should change the type of device offered, or simply inform expectations about outcomes, remains an active area of research.³⁴ This is a conversation worth having with your medical team if you or a family member is physically frail.

Self-Powered Pacemakers and AI-Driven Programming

The battery problem may eventually disappear altogether. Several research groups are developing energy harvesters that convert the heart’s own mechanical motion into electricity. One experimental system implanted in a pig successfully powered a functioning pacemaker using a piezoelectric generator driven by heartbeats, producing enough current to pace the heart without any external battery.³⁵ Other groups have demonstrated similar concepts in animal models using vibration-based harvesters attached to the heart’s surface.³⁶ These remain experimental, but if successful, they would eliminate battery-driven replacement surgeries entirely.

On the software side, artificial intelligence is being explored to allow pacemakers to self-adjust their programming based on a patient’s changing activity and physiological signals. Natural language processing and reinforcement learning are among the approaches being investigated to integrate data from multiple sources and enable more autonomous device behavior.³⁷ A pacemaker that continuously learns your individual patterns and adjusts without waiting for a clinic visit would represent a significant shift from today’s devices, which largely operate within static parameters set at implantation or periodic check-ups.

Device Reuse in Low-Resource Settings

Outside wealthy countries, millions of people who need pacemakers simply cannot access them. Programs to recover and resterilize devices from deceased patients in high-income countries have shown promise: one large U.S. program collected over 3,100 donated devices, of which about 21% had sufficient remaining battery life for potential reuse.³⁸ Available evidence has not shown increased morbidity or mortality from properly sterilized reused devices, though logistical, legal, and ethical barriers continue to limit these programs.³⁹ For the global question of “what is the best pacemaker,” the answer for many patients is simply whichever one they can actually get.